Of baseball and enhancement bondage
By Pete Shanks,
San Francisco Chronicle
| 09. 26. 2005
Baseball fans around the nation have been conducting their own straw poll about human enhancement, and they don't like it. Rafael Palmeiro has practically been driven out of the game, Mark McGwire is now seen as more cartoon than hero, and Jason Giambi is treated with widespread derision.
Then there is Barry Bonds.
Bonds is -- as usual -- a lightning rod for everyone's feelings, a walking paradox who illustrates without even trying just how complex these issues are. He told reporters before his first game in Washington, D.C., that there are more serious issues than steroids, but all that did was increase the hype about his appearance. And he lived up to it.
Bonds getting booed is not unusual in a road game. But in Washington, he was booed by fans who were on their feet as he homered to the upper deck -- clapping at the same time they were jeering. Whether they were right or wrong about Bonds (who denies ever knowingly taking illegal substances), there couldn't be a more dramatic illustration of the conflicts we feel...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...